kentucky semaglutide gastrointestinal obstruction class action glp-1 ileus lawsuit gastric intestinal in law office glp -1 digestive blockage legal team kentucky Pharmaceutical giant Novo Nordisk is – obstruction lawyer in – glp-1 gi obstruction class action

WHO IT'S FOR Anyone using or planning to start a GLP-1 medication semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or liraglutide (Saxenda, Victoza)

Studies show that when people quit GLP-1 medications after a year, they tend to regain up to two-thirds of the weight they lost

For most people, yesat least partially

4,5 Clinical outcomes Across phase II data for the once-daily, non-peptide GLP-1R agonist orforglipron in obese adults without diabetes, mean weight loss of 9.414.7% 6 was reported by week 36, depending on the dose, as compared to 2.3% with placebo

Orforglipron (LY3502970), a novel, oral nonpeptide glucagonlike peptide1 receptor agonist: A Phase 1a, blinded, placebocontrolled, randomized, singleand multipleascendingdose study in healthy participants